[S02] Sheep Anti-Human Apolipoprotein (a) Antiserum10S-SP1b
|Antigen:||Human Apolipoprotein (a)|
Specifically binds to human Lp (a) and apo (a). No cross-reaction to apo B-100/48; mino to plasminogen (Cross-reactivity to plasminogen was removed by passing plasminogen-Sepharose™ affinity column). Dilution for immunoblot and ELISA range: 1,000 to 200,000.
The antibody can be used for detection of Lp(a) and apo (a) in human plasma and lipoproteins, using immunoassays or immunoblots.
|Storage:||-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.|
The Lipoprotein (a) [Lp(a)] structure is similar to that of low density lipoprotein (LDL), regarding size and lipid composition of the particles and the presence of apolipoprotein B-100 (apo B-100). In addition to apo B-100, Lp(a) has a second protein, apolipoprotein (a) [apo (a)], which the molecular weight of that glycoprotein varies widely from 400 to 700 kDa. (Maranhão et al., 2013)
Previous research has shown that apo (a) has a similar structure with plasminogen and contains a serine protease domain and two types of plasminogen-like kringle domains. (McLean et al., 1987) The plasma concentration of human lipoprotein[a], Lp[a], is highly correlated with coronary artery disease. (Gaubatz et al., 1990)
Gaubatz, J.W., K. I. Ghanem, J. Jr. Guevara, M. L. Nava, W. Patsch, and J. D. Morrisett. “Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a].” J. Lipid Res. 31.4 (1990):603-13.
Mclean, John W., James E. Tomlinson, Wun-Jing Kuang, Dan L. Eaton, Ellson Y. Chen, Gunther M. Fless, Angelo M. Scanu, and Richard M. Lawn. "CDNA Sequence of Human Apolipoprotein(a) Is Homologous to Plasminogen." Nature 330.6144 (1987): 132-37.
Maranhão, Raul Cavalcante, Priscila Oliveira Carvalho, Celia Cassaro Strunz, and Fulvio Pileggi. "Lipoprotein (a): Structure, Pathophysiology and Clinical Implications." Arquivos Brasileiros De Cardiologia 103.1 (2014): 76-84.